Period10 Mar 2023

Media coverage

2

Media coverage

  • Title-BERGENBIO ANNOUNCES FIRST PATIENT DOSED IN PHASE 1B/2A TRIAL EVALUATING BEMCENTINIB IN 1ST LINE NON-SMALL CELL LUNG CANCER WITH STK11 MUTATIONS
    Media name/outletM2 PressWIRE
    Country/TerritoryUnited States
    Date10/03/23
    PersonsRajwanth Veluswamy
  • Title-BERGENBIO ANNOUNCES FIRST PATIENT DOSED IN PHASE 1B/2A TRIAL EVALUATING BEMCENTINIB IN 1ST LINE NON-SMALL CELL LUNG CANCER WITH STK11 MUTATIONS
    Media name/outletENP Newswire
    Country/TerritoryUnited Kingdom
    Date10/03/23
    PersonsRajwanth Veluswamy